Lower proportion of CD19⁺IL-10⁺ and CD19⁺CD24⁺CD27⁺ but not CD1d⁺CD5⁺CD19⁺CD24⁺CD27⁺ IL-10⁺ B cells in children with autoimmune thyroid diseases

Figures & data

Table 1. Demographic and serological data of all 53 investigated patients.

	GD untreated	GD treated	HT untreated	HT treated	Control
Patients/Samples	12/13 (92.3%)	17/46 (37%)	10/11 (90.9%)	10/15 (66.7%)	15/15 (100%)	–
Age (years)	12.5 ± 3.5	12.7 ± 4.4	13.3 ± 2.9	13.7 ± 3.4	13.1 ± 3.1	NS*, NS**, NS***, NS****
Gender (female)	9/13 (69.2%)	32/46 (69.6%)	10/11 (90.9%)	15/15 (100%)	11/15 (73.3%)	–
TSH (uIU/ml) (0.32–5.00)	0.8 ± 1.2	5.1 ± 15.7	11.9 ± 11.1	5.5 ± 5.9	2.8 ± 1.5	p<.01*, NS**, p<.01***, NS****
fT4 (ng/ml) (0.71–1.55)	2.9 ± 1.7	1.2 ± 0.8	0.6 ± 0.5	1.1 ± 0.1	1.8 ± 1.0	p<.01*, NS**, p<.05***, NS****
fT3 (pg/ml) (2.6–5.4)	8.4 ± 5.8	5.0 ± 3.9	2.3 ± 1.1	3.7 ± 0.0	3.5 ± 0.34	p<.01*, NS**, NS***, NS****
Anti-TG (IU/ml) (<115)	941.6 ± 1408.0	144.2 ± 108.6	943.4 ± 1253.8	2106.9 ± 1816.2	28.6 ± 3.7	p<.01*, p<.05**, p<.01***, p<.01****
Anti-TPO (IU/ml) (<34)	235.0 ± 198.2	177.9 ± 76.0	438.3 ± 172.5	354.8 ± 213.9	13.1 ± 13.9	p < 0.05*, p < 0.05**, p < 0.01***, p < 0.01****
TSHR-Ab (U/l) (0–1.7)	13.9 ± 12.5	11.3 ± 12.8	0.7 ± 0.5	0.9 ± 0.6	0.71 ± 0.48	p<.01*, p<.01**, NS***, NS****

Data are expressed as number of patients/total samples (%) or as a mean value SD. The normal range is shown for thyroid hormones and antibodies in parenthesis.

* Statistically significant difference between GD untreated group and control.

** Statistically significant difference between GD treated group and control.

*** Statistically significant difference between HT untreated group and control.

**** Statistically significant difference between HT treated group and control.

Figure 2. Presentation of alterations in frequencies of different IL-10-producing B and regulatory B cells within total lymphocytes (A-D) and CD19+ B cells (E-H) in study groups including: CD19⁺IL-10⁺ (A, E), CD19⁺CD24⁺CD27⁺IL-10⁺ (B, F), CD1d⁺CD5⁺CD19⁺IL-10⁺ (C, G), CD1d⁺CD5⁺CD24⁺CD27⁺IL-10⁺ (D, H).

Figure 3. Graphical presentation of changes in IL-10 production within total CD19⁺ B cells (A) and 3 different phenotypes of regulatory B cells: CD24⁺CD27⁺CD19⁺ (B); CD1d⁺CD5⁺CD19⁺ (C); CD1d⁺CD5⁺CD19⁺CD24⁺CD27⁺ (D).

Figure 4. Changes in percentage of putative phenotypes of regulatory B cells within lymphocytes (row above) and CD19+ B cells (row below) in study groups: CD19⁺CD24⁺CD27⁺ (A, D), CD1d⁺CD5⁺CD19⁺ (B, E), CD1d⁺CD5⁺CD24⁺CD27⁺CD19⁺ (C, F).